Immunotherapy with Cells

Overview

Journal Hematology Am Soc Hematol Educ Program

Specialty Hematology

Date 2020 Dec 4

PMID 33275723

Authors

Elise A Chong

David L Porter

Affiliations

Soon will be listed here.

Abstract

Both older and newer cell therapies have demonstrated impressive responses in otherwise poor-prognosis lymphomas. Consequently, cellular therapy now plays a major role in the management of many non-Hodgkin lymphomas. In this article, we examine the role of chimeric antigen receptor (CAR) T cells, allogeneic stem cell transplantation, and virus-directed T cells for treatment of lymphomas. We review the current indications for CAR T cells and discuss our clinical approach to selecting and treating patients with aggressive B-cell lymphomas to receive CD19-directed CAR T cells. In addition, we highlight newer cell therapies and provide an overview of promising future approaches that have the potential to transform immunotherapy with cells to treat lymphomas.

References

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Gardner R, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A . Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019; 134(24):2149-2158. PMC: 6908832. DOI: 10.1182/blood.2019001463. View

Fraietta J, Lacey S, Orlando E, Pruteanu-Malinici I, Gohil M, Lundh S . Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018; 24(5):563-571. PMC: 6117613. DOI: 10.1038/s41591-018-0010-1. View

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

Smith S, Burns L, Van Besien K, LeRademacher J, He W, Fenske T . Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013; 31(25):3100-9. PMC: 3753702. DOI: 10.1200/JCO.2012.46.0188. View

Cappell K, Sherry R, Yang J, Goff S, Vanasse D, McIntyre L . Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020; 38(32):3805-3815. PMC: 7655016. DOI: 10.1200/JCO.20.01467. View

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

Kochenderfer J, Somerville R, Lu T, Yang J, Sherry R, Feldman S . Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017; 25(10):2245-2253. PMC: 5628864. DOI: 10.1016/j.ymthe.2017.07.004. View

June C, Maus M, Plesa G, Johnson L, Zhao Y, Levine B . Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014; 63(9):969-75. PMC: 4142345. DOI: 10.1007/s00262-014-1568-1. View

10.

Frigault M, Dietrich J, Martinez-Lage M, Leick M, Choi B, DeFilipp Z . Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019; 134(11):860-866. PMC: 7022436. DOI: 10.1182/blood.2019001694. View

11.

Frey N, Gill S, Hexner E, Schuster S, Nasta S, Loren A . Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2020; 38(25):2862-2871. PMC: 8265376. DOI: 10.1200/JCO.19.03237. View

12.

Dean E, Mhaskar R, Lu H, Mousa M, Krivenko G, Lazaryan A . High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4(14):3268-3276. PMC: 7391155. DOI: 10.1182/bloodadvances.2020001900. View

13.

Qasim W . Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019; 94(S1):S50-S54. DOI: 10.1002/ajh.25399. View

14.

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

15.

Nastoupil L, Jain M, Feng L, Spiegel J, Ghobadi A, Lin Y . Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128. PMC: 7499611. DOI: 10.1200/JCO.19.02104. View

16.

Brudno J, Somerville R, Shi V, Rose J, Halverson D, Fowler D . Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 2016; 34(10):1112-21. PMC: 4872017. DOI: 10.1200/JCO.2015.64.5929. View

17.

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

18.

Jain T, Bar M, Kansagra A, Chong E, Hashmi S, Neelapu S . Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019; 25(12):2305-2321. DOI: 10.1016/j.bbmt.2019.08.015. View

19.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S . Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017; 9(374). DOI: 10.1126/scitranslmed.aaj2013. View

20.

Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P . Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2019; 130(2):733-747. PMC: 6994129. DOI: 10.1172/JCI121127. View